Compare Marathon Digital Holdings Inc (MARA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Digital Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Marathon Digital Holdings Inc trades at $9.69 (market cap $3.83B), while Vertex Pharmaceuticals Incorporated trades at $513.16 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 33.3× Marathon Digital Holdings Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Digital Holdings Inc for 22 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MARA | VRTX | |
|---|---|---|
Market Cap | $3.83B | $127.55B |
Volume | 47,742,698 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $22.84 | $557.96 |
52-Week Low | $6.73 | $407.37 |
Typical Hold Time | 22 Days | 120 Days |
Enterprise Value | $5.87B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MARA stock trades at $10.36, down 5.56% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported significant losses with a net income margin of -429.71% in 2026, though valuation ratios appear attractive with P/E of 3.37 and EV/EBITDA of 3.31. Recent earnings have consistently missed expectations, with Q2 2026 EPS of -1.60 versus expected 0.17.
The outlook remains challenging due to persistent losses and negative cash flow from operations. Analyst consensus is divided with 45% buy ratings and a $13.25 price target, suggesting 28% upside potential. Key risks include execution challenges, competitive pressures, and reliance on financing activities to sustain operations.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
